Summary

Treatment with alemtuzumab is associated with durable improvements in magnetic resonance imaging (MRI) disease activity in patients with active relapsing-remitting multiple sclerosis. This article presents the 3-year results from An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (NCT00930553), an ongoing extension study of the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) series of studies.